Mass General Hospital

Harvard Medical School

Navigation

Welcome to the MGH Center for Women’s Mental Health

Welcome

Welcome to The Ammon-Pinizzotto Center for Women’s Mental Health at MGH. Our Center, established in 1989, has been renamed following the generous gift from Carol Ammon and Dr. Marie Pinizzotto. These resources will be used to realize the overarching mission of the Center.

This website provides a range of current information including discussion of new research findings in women’s mental health and how such investigations inform day-to-day clinical practice. Despite the growing number of studies being conducted in women’s health, the clinical implications of such work are frequently controversial, leaving patients with questions regarding the most appropriate path to follow. Providing these resources to patients and their doctors so that individual clinical decisions can be made in a thoughtful and collaborative fashion dovetails with the mission of our Center.

The National Pregnancy Registry for Psychiatric Medications:

All pregnant women between the ages of 18-45 with a history of psychiatric illness are eligible to enroll in the registry. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics and antidepressants during pregnancy.  We are currently seeking both controls and those being treated with atypical antipsychotics and/ or antidepressants. For more information, please visit this page, call 1-866-961-2388 or e-mail registry@partners.org.

Course of ADHD in Pregnancy and the Postpartum

Are you pregnant? Do you have a history of ADHD?

If you are less than 20 weeks pregnant and have a history of ADHD, you may be eligible to take part in an observational research study for women maintaining, decreasing, or discontinuing psychostimulants during pregnancy and the postpartum. Women who participate will have 6 study visits that can be completed in-person at Massachusetts General Hospital or over the phone.

For more information, please call (617)726-2912 or email the study coordinator at onoe@partners.org

 EnBrace HR for MDD Relapse Prevention in         Women Trying to Conceive and Early Pregnancy:

 

Are you pregnant or planning a pregnancy? Do you feel depressed or have a history of depression? If you are less than 28 weeks pregnant or trying to conceive and have experienced depression now or in the past, you may be eligible to take part in a research study for the treatment of depression with a prenatal supplement. For more information, please visit this page, call Taylor at 617-643-9284 or email tchurch1@partners.org

 

 

Lifestyle Intervention Research Study Opportunity:

Are you pregnant or planning to become pregnant? Do you have a history of depression? Do you want to lose weight or have a healthier lifestyle? You may be eligible to participate in a research study evaluating a new lifestyle intervention for weight loss. Participants will receive 10 sessions of therapy at no cost to you.

If you are interested in participating or would like additional information, please call Samantha at 617-643-2076.

 

The MGH Center for Women’s Mental Health

Perinatal and Reproductive Psychiatry Program

Simches Research Building

185 Cambridge St Suite 2200

Boston, MA 02114

 

To make an appointment:

Massachusetts General Hospital Clinical Program: (617) 724-7792

Location of appointments: 

Wang Ambulatory Care Center, Massachusetts General Hospital

15 Parkman St., Floor 8

Boston, MA 02114-3117 

Latest News from our Blog

  • Fluvoxamine and Pregnancy: Is There a Right Choice?

    May 16, 2018

      Every day, we see women in our clinic who are deciding whether to continue a selective serotonin reuptake inhibitor (SSRI) for management of depression or anxiety during pregnancy. As a class, SSRI use during pregnancy is generally not associated with a significant overall risk for major congenital malformations. While we often do think about SSRIs as ...

    Read more

  • Female Sexual Dysfunction: New Treatments on the Way

    May 15, 2018

      Hypoactive sexual desire disorder (HSDD) is the most common type of female sexual dysfunction, affecting approximately 10% of all adult women. In certain populations of women that we see in our clinic, including women treated with serotonergic antidepressants and perimenopausal women, rates of sexual dysfunction are even higher.   Currently, flibanserin is the only medication approved ...

    Read more

  • United Kingdom Limits the Use of Valproate in Reproductive Age Women

    May 9, 2018

      Last year France banned the use of the antiepileptic during valproate in certain populations of reproductive age women.  Now the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has banned the use of valproate in women of childbearing age unless they are enrolled in a pregnancy prevention program (PPP).  From the initial report, it ...

    Read more

  • Event: Perinatal Mental Health Awareness & Advocacy Day 2018

    May 7, 2018

    For those in the Boston area, this Wednesday May 9th is Perinatal Mental Health Awareness & Advocacy Day 2018.  This event will be held at the Great Hall, Massachusetts State House at 24 Beacon St. in Boston from 12PM to 3PM.  This is a free event for all who are interested in promoting awareness of perinatal ...

    Read more

  • Fetal exposure to depression: How does ‘dose’ figure in?

    May 7, 2018

    The following post was first published in OB/GYN News. Please see our OB/GYN News archives here. Publish date: April 23, 2018 The last two decades have seen an ever-growing number of reports on risks of fetal exposure to medicines used to treat depression during pregnancy. These reports have described issues ranging from estimated risk of congenital malformations following fetal exposure ...

    Read more

  • In Brief: What’s the Connection Between Alcohol and Premenstrual Symptoms?

    May 7, 2018

    When we meet with women reporting premenstrual symptoms, we often recommend that they avoid the use of alcohol.   Analyzing 19 previously published studies of alcohol and PMS, researcher found that risk for PMS risk was 45% higher in women who reported drinking than in non-drinkers.  Women who were heavy drinkers, drinking more than one drink ...

    Read more

Read more from our Blog

Recent Awards

banner_postpartum-depression

Awarded by Healthline.com

Awarded by Feedspot.com

 

 

 

 

 

 

Awarded by Feedspot.com

Awarded by Cables and Sensors